Gilead Sciences, Inc. announced that the US Patent & Trademark Office (PTO) has completed the first of four re-examination proceedings and has confirmed the patentability of US Patent No. 6,043,230, which covers a method of use for Viread (tenofovir disoproxil fumarate). The US PTO has not announced its ruling on the remaining three Viread patents under review.
The four US PTO review proceedings were initiated July 2007 in response to a challenge issued by the Public Patent Foundation (PUBPAT) in March 2007 for US Patents No. 5,922,695; 5,977,089; 5,935,946; and 6,043,230. In its request for the re-examinations, PUBPAT claimed that prior art existed that would have impacted the issuance of the original patents.
Upon completion of the first re-examination proceeding, the US PTO has confirmed the patentability of US Patent No. 6,043,230 with no reduction in the scope of the claims.
Source: www.pharmabiz.com
No comments:
Post a Comment